Licensing the STOX Suite

Use licenses are required for all Steritas clinical outcome assessments

Steritas is the sole licensing entity of the instruments in the STOX® Suite and we thank you for signaling your interest in The Great Taper^TM. All uses of Steritas clinical outcome assessments require a license, whether you are an academic researcher, biotech start-up, public health investigator, large pharmaceutical entity, or clinical research organization.

Maintaining scientific rigor in the use of our COAs is essential to discovery. For unfunded academic research, we welcome applications for no-fee licenses to the STOX Suite and access to the STOX Digital Platform. This is another way we honor the aspirations of The Great Taper.

We will structure your license agreement to support the scope of use and the needs of your team.

Steroids are being held accountable in a growing list of clinical trials for inflammatory disease drug candidates

The Steritas STOX Suite provides the only outcome measures for clinical research that compare efficacy and safety of new drug protocols to conventional steroid therapy.

The STOX Suite is licensed to measure steroid-toxicity in a growing list of Phase 3 clinical trials for inflammatory and autoimmune disease drug candidates. In June 2026, REPLENISH (secukinumab in polymyalgia rheumatica), GCAptAIN (secukinumab in giant cell arteritis), and INDIGO (obexelimab in IgG4-related disease) each reported steroid-toxicity reduction measured with a pre-specified GTI endpoint.

Steroids are being held accountable in a growing list of clinical trials for inflammatory disease drug candidates

The Steritas STOX Suite provides the only outcome measures for clinical research that compare efficacy and safety of new drug protocols to conventional steroid therapy.

Licenses are customized to your research

Use licenses are required for all Steritas clinical outcome assessments

Steroids are being held accountable in a growing list of clinical trials for inflammatory disease drug candidates

STOX Suite adopted globally to counter the hidden epidemic of steroid-toxicity

Steroids are being held accountable in a growing list of clinical trials for inflammatory disease drug candidates

1100 sites across 80 countries